Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose


#145794

106pages

GBI Research

$ 3500

In Stock


GBI Research, the leading business intelligence provider, has released its latest research, Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose, which provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes insights into the seasonal influenza vaccine R&D pipeline and gives profiles of promising vaccines, as well as exploring the competitive landscape through profiles for the top companies. Key trends in terms of M&A and licensing agreements are also analyzed.

GBI Research expects the market to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the 20112018 period from $2.9 billion in 2011 to $3.8 billion by 2018, driven by growing awareness, increasing vaccination coverage and rising government support for immunization against seasonal influenza. On the other hand, limited production capacity, high investment and strict regulations may act as barriers to entry.

The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germanys market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.

GBI Researchs analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.

Scope

  • Data and analysis on the seasonal influenza vaccine market in the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan
  • Market forecasts for seasonal influenza vaccines until 2018
  • Market data on geographical landscape in terms of country, vaccination coverage, public and private contribution to the total number of doses, vaccine price and market size
  • Key drivers and restraints that have had a significant impact on the market
  • Regulatory landscape, including the approval process and an overview of the regulatory authorities in the top seven countries
  • Competitive landscape of the seasonal influenza vaccine market in the top seven countries including top companies profiles, namely Sanofi, Johnson & Johnson, GlaxoSmithKline Biologicals, Novartis Vaccines and AstraZeneca
  • Key M&A activities and licensing agreements that have taken place between 2009 and mid-2012

Reasons to buy

  • Build effective strategies to launch pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
  • Develop key strategic initiatives by studying top competitors key strategies
  • Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms able to produce safer and more efficacious first-in-class vaccines
Table of Contents

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Seasonal Influenza Vaccine Market in Top Seven Countries – Executive Summary
2.1 Top Seven Countries Set to Grow at a Moderate CAGR of 3.9% during the Forecast Period
2.2 Increasing Government Efforts are Driving the Seasonal Influenza Vaccine Market
2.3 Novel Vaccines and New Production Technologies will Revolutionize the Seasonal Influenza Market
2.4 Major Pharmaceutical Companies’ Strong Focus on Entering the Seasonal Influenza Vaccine Market

3 Seasonal Influenza Vaccines Market in Top Seven Countries: Introduction
3.1 GBI Research Report Guidance

4 Seasonal Influenza Vaccine Market in Top Seven Countries: Market Overview
4.1 Production Cycle for Seasonal Influenza Vaccines
4.2 Seasonal Influenza Vaccine Market in Top Seven Countries
4.2.1 Vaccination Pattern
4.2.1.1 Population
4.2.1.2 Vaccination Coverage
4.2.1.3 Vaccination Coverage
4.2.1.4 Total Number of Doses
4.2.2 Total Revenue
4.3 Drivers and Restraints
4.3.1 Drivers
4.3.1.1 Threat of Pandemic Influenza
4.3.1.2 Emergence of Novel Production Technologies and Vaccines
4.3.1.3 Increase in Geriatric Population
4.3.1.4 Government Support for Vaccination
4.3.2 Restraints
4.3.2.1 Entry Barriers to the Seasonal Influenza Vaccine Market
4.3.2.2 Variable Demand
4.3.2.3 Perception of Influenza as Benign Disease in Children

5 Seasonal Influenza Vaccine Market in Top Seven Countries: Geographical Landscape
5.1 The US
5.1.1 Vaccination Pattern
5.1.1.1 Population
5.1.1.2 Vaccinated Population Coverage
5.1.1.3 Vaccination Coverage
5.1.1.4 Number of Doses per Person
5.1.1.5 Total Number of Doses
5.1.1.6 Dose Contribution
5.1.1.7 Number of Public and Private Doses
5.1.2 Vaccine Cost
5.1.3 Total Revenue
5.2 Drivers and Restraints
5.2.1 Drivers
5.2.1.1 Recommendations for Annual Seasonal Influenza Vaccination
5.2.1.2 Increasing Seasonal Influenza Awareness
5.2.1.3 Vaccination is More Convenient
5.2.1.4 Growing Elderly Population
5.2.2 Barriers
5.2.2.1 Low Contribution from the Government
5.2.2.2 High Price of Vaccine
5.3 The UK
5.3.1 Vaccination Pattern
5.3.1.1 Population
5.3.1.2 Vaccinated Coverage
5.3.1.3 Vaccination Coverage
5.3.1.4 Number of Doses per Person
5.3.1.5 Total Number of Doses
5.3.1.6 Dose Contribution
5.3.1.7 Number of Public and Private Doses
5.3.2 Vaccine Cost
5.3.3 Total Revenue
5.4 Drivers and Restraints
5.4.1 Drivers
5.4.1.1 Increasing Vaccination Coverage among Elderly Population
5.4.1.2 Government Support for Immunization
5.4.2 Restraint
5.4.2.1 Low Vaccination Coverage for Influenza in Children and Adults
5.5 France
5.5.1 Vaccination Pattern
5.5.1.1 Population
5.5.1.2 Vaccination Coverage
5.5.1.3 Vaccination Coverage
5.5.1.4 Number of Doses per Person
5.5.1.5 Total Number of Doses
5.5.1.6 Doses Contribution
5.5.1.7 Number of Public and Private Doses
5.5.2 Vaccine Cost
5.5.3 Total Revenue
5.6 Drivers and Restraints
5.6.1 Drivers
5.6.1.1 Government Support for Immunization
5.6.1.2 Low Price for the Vaccine
5.6.2 Restraints
5.6.2.1 Stagnant Vaccination Coverage
5.7 Italy
5.7.1 Vaccination Pattern
5.7.1.1 Population
5.7.1.2 Vaccination Coverage
5.7.1.3 Vaccination Coverage
5.7.1.4 Number of Doses per Person
5.7.1.5 Total Number of Doses
5.7.1.6 Dose Contribution
5.7.1.7 Number of Public and Private Doses
5.7.2 Vaccine Cost
5.7.3 Total Revenue
5.8 Drivers and Restraints
5.8.1 Drivers
5.8.1.1 Government Support for Immunization against Seasonal Influenza
5.8.1.2 Increasing Elderly Population
5.8.2 Restraints
5.8.2.1 Lack of Awareness Regarding Disease Severity and Immunization Benefits
5.9 Spain
5.9.1 Vaccination Pattern
5.9.1.1 Population
5.9.1.2 Vaccination Coverage
5.9.1.3 Vaccination Coverage
5.9.1.4 Number of Doses per Person
5.9.1.5 Total Number of Doses
5.9.1.6 Dose Contribution
5.9.1.7 Number of Public and Private Doses
5.9.2 Vaccine Cost
5.9.3 Total Revenue
5.10 Drivers and Restraints
5.10.1 Drivers
5.10.1.1 Government Support for Immunization
5.10.1.2 Increasing Elderly Population
5.10.1.3 Low Vaccine Cost
5.10.2 Restraints
5.10.2.1 Lack of Awareness Regarding Disease and Vaccination
5.11 Germany
5.11.1 Vaccination Pattern
5.11.1.1 Population
5.11.1.2 Vaccination Coverage
5.11.1.3 Vaccination Coverage
5.11.1.4 Number of Doses per Person
5.11.1.5 Total Number of Doses
5.11.1.6 Dose Contribution
5.11.1.7 Number of Public and Private Doses
5.11.2 Vaccine Cost
5.11.3 Total Revenue
5.12 Drivers and Restraints
5.12.1 Drivers
5.12.1.1 Government Support for Immunization against Seasonal Influenza
5.12.1.2 Recommendations by Healthcare Workers
5.12.1.3 Increasing Aging Population
5.12.2 Restraints
5.12.2.1 Low Vaccination Rates among Adults and Children
5.12.2.2 High Vaccine Cost
5.13 Japan
5.13.1 Vaccination Pattern
5.13.1.1 Population
5.13.1.2 Vaccinated Population Contribution
5.13.1.3 Vaccination Coverage
5.13.1.4 Number of Doses per Person
5.13.1.5 Total Number of Doses
5.13.2 Vaccine Cost
5.13.3 Total Revenue
5.14 Drivers and Restraints
5.14.1 Drivers
5.14.1.1 Influenza Immunization Program
5.14.1.2 Incidences of Pandemic Influenza
5.14.1.3 Rapidly Growing Elderly Population
5.14.1.4 Subsidized Immunization for the Elderly
5.14.2 Restraints
5.14.2.1 Non-reimbursement of Influenza Vaccination Costs
5.14.2.2 Limited Availability Period for Subsidized Vaccines
5.14.2.3 Lack of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan
5.14.2.4 High Vaccine Cost

6 Seasonal Influenza Vaccine Market in Top Seven Countries: Regulatory Landscape
6.1 Registration Process and Regulations for Vaccines in the US
6.2 Registration Process and Regulations for Vaccines in the EU
6.3 Registration Process and Regulations for Vaccines in Japan

7 Seasonal Influenza Vaccine Market in Top Seven Countries: Pipeline Analysis
7.1 Summary
7.2 Research and Development Pipeline by Phase
7.3 Promising Vaccines under Clinical Development
7.3.1 Flu Q-QIV
7.3.1.1 Overview
7.3.1.2 Clinical Study Details
7.3.2 Optaflu
7.3.2.1 Overview
7.3.2.2 Clinical Study Details
7.3.3 Fluzone QIV
7.3.3.1 Overview
7.3.3.2 Clinical Study Details
7.3.4 FluBlok
7.3.4.1 Overview
7.3.4.2 Clinical Trial Details
7.3.5 Q-LAIV Flu Vac
7.3.5.1 Overview
7.3.5.2 Clinical Trial Details

8 Seasonal Influenza Vaccine Market in Top Seven Countries: Competitive Landscape
8.1 Market Share Analysis
8.2 Competitive Profiling
8.2.1 Sanofi Pasteur
8.2.1.1 Overview
8.2.1.2 Major Marketed Products
8.2.1.3 SWOT Analysis
8.2.2 GlaxoSmithKline
8.2.2.1 Overview
8.2.2.2 Major Marketed Products
8.2.2.3 SWOT Analysis
8.2.3 Novartis Vaccines
8.2.3.1 Overview
8.2.3.2 Major Marketed Products
8.2.3.3 SWOT Analysis
8.2.4 AstraZeneca
8.2.4.1 Overview
8.2.4.2 Major Marketed Products
8.2.4.3 SWOT Analysis

9 Seasonal Influenza Vaccine Market in Top Seven Countries: Strategic Consolidation
9.1 Overview
9.1.1 Segmentation by Deal Type
9.1.2 Segmentation by Year
9.2 Major Merger and Acquisition Deals, 2009–2012
9.2.1 Intrexon Acquires Neugenesis
9.2.2 Grupo Ferrer Internacional Completes Acquisition of 50% Stake in Alentia Biotech from Laboratorios Farmaceuticos
9.2.3 Nexus Merges with HX Diagnostics
9.2.4 Mymetics Acquires Virosome Biologicals
9.2.5 Abbott Laboratories Acquires Solvay Pharmaceuticals
9.2.6 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
9.2.7 Johnson & Johnson Acquires Crucell
9.2.8 VBI Vaccines Acquires Epixis
9.2.9 Sanofi Pasteur Acquires Remaining 50% Joint Venture Interest in Sanofi Pasteur-Daiichi Sankyo Vaccines
9.2.10 Segmentation by Geography
9.2.11 Segmentation by Year
9.3 Major Licensing Agreements, 2009–2012
9.3.1 Baxter International Expands its Licensing Agreement with Takeda Pharma
9.3.2 AltraVax Enters into Licensing Agreement with Maxygen
9.3.3 iBio Enters into Licensing Agreement with G-Con
9.3.4 NasVax Extends its Research Agreement with Novartis
9.3.5 Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
9.3.6 Segmentation by Geography
9.3.7 Segmentation by Year
9.4 Major Partnership Deals
9.4.1 Merck Enters into Agreement with CSL Biotherapies
9.4.2 GenVec Enters into an Agreement with SAIC-Frederick
9.4.3 UMN Pharma Enters into Co-Development Agreement with API
9.4.4 Daiichi Sankyo Forms Joint Venture with Kitasato Institute Research
9.4.5 Novartis International Enters into an Agreement with Synthetic Genomics Vaccines
9.4.6 PPD Enters into Collaboration Agreement with Southern Research Institute
9.4.7 Segmentation by Geography
9.4.8 Segmentation by Year

10 Seasonal Influenza Vaccine Market in Top Seven Countries: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Secondary Research
10.4.2 Primary Research
10.4.3 Model for Estimation of Seasonal Influenza Vaccine Market
10.5 Geographical Landscape
10.6 Pipeline Analysis
10.7 Competitive Landscape
10.8 Strategic Consolidations
10.9 Contact Us
10.10 Disclaimer

Table 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population (000), 20112018 15
Table 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 20112018 16
Table 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Overall Vaccination Coverage (000), 20112018 17
Table 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (000), 20112018 17
Table 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Total Number of Doses (000), 20112018 18
Table 6: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group (000), 20112018 18
Table 7: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 20112018 19
Table 8: Seasonal Influenza Vaccine Market, The US, Population (000), 20112018 23
Table 9: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 20112018 24
Table 10: Seasonal Influenza Vaccine Market, The US, Overall Vaccination Coverage (000), 20112018 25
Table 11: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (000), 20112018 25
Table 12: Seasonal Influenza Vaccine Market, The US, Total Number of Doses (000), 20112018 26
Table 13: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group (000), 20112018 27
Table 14: Seasonal Influenza Vaccine Market, The US, Number of Doses by Sector (000), 20112018 27
Table 15: Seasonal Influenza Vaccine Market, The US, Vaccine Cost ($), 20112018 27
Table 16: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 20112018 28
Table 17: Seasonal Influenza Vaccine Market, The UK, Population (000), 20112018 31
Table 18: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group (%), 20112018 32
Table 19: Seasonal Influenza Vaccine Market, The UK, Overall Vaccination Coverage (000), 20112018 33
Table 20: Seasonal Influenza Vaccine Market, The UK, Vaccination Coverage by Age Group (000), 20112018 33
Table 21: Seasonal Influenza Vaccine Market, The UK, Total Number of Doses (000), 20112018 34
Table 22: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group (000), 20112018 34
Table 23: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Sector (000), 20112018 35
Table 24: Seasonal Influenza Vaccine Market, The UK, Vaccine Cost ($), 20112018 35
Table 25: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 20112018 36
Table 26: Seasonal Influenza Vaccine Market, France, Population (000), 20112018 38
Table 27: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 20112018 39
Table 28: Seasonal Influenza Vaccine Market, France, Overall Vaccination Coverage (000), 20112018 40
Table 29: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (000), 20112018 40
Table 30: Seasonal Influenza Vaccine Market, France, Total Number of Doses (000), 20112018 41
Table 31: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group (000), 20112018 41
Table 32: Seasonal Influenza Vaccine Market, France, Number of Doses by Sector Contribution (000), 20112018 42
Table 33: Seasonal Influenza Vaccine Market, France, Vaccine Cost ($), 20112018 42
Table 34: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 20112018 43
Table 35: Seasonal Influenza Vaccine Market, Italy, Population (000), 20112018 45
Table 36: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 20112018 46
Table 37: Seasonal Influenza Vaccine Market, Italy, Overall Vaccination Coverage (000), 20112018 47
Table 38: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (000), 20112018 47
Table 39: Seasonal Influenza Vaccine Market, Italy, Total Number of Doses (000), 20112018 48
Table 40: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group (000), 20112018 48
Table 41: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Sector Contribution (000), 20112018 49
Table 42: Seasonal Influenza Vaccine Market, Italy, Vaccine Cost ($), 20112018 49
Table 43: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 20112018 50
Table 44: Seasonal Influenza Vaccine Market, Spain, Population (000), 20112018 52
Table 45: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 20112018 53
Table 46: Seasonal Influenza Vaccine Market, Spain, Overall Vaccination Coverage (000), 20112018 54
Table 47: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (000), 20112018 54
Table 48: Seasonal Influenza Vaccine Market, Spain, Total Number of Doses (000), 20112018 55
Table 49: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group (000), 20112018 55
Table 50: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Sector Contribution (000), 20112018 56
Table 51: Seasonal Influenza Vaccine Market, Spain, Vaccine Cost ($), 20112018 56
Table 52: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 20112018 57
Table 53: Seasonal Influenza Vaccine Market, Germany, Population (000), 20112018 59
Table 54: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 20112018 60
Table 55: Seasonal Influenza Vaccine Market, Germany, Overall Vaccination Coverage (000), 20112018 61
Table 56: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (000), 20112018 61
Table 57: Seasonal Influenza Vaccine Market, Germany, Total Number of Doses (000), 20112018 62
Table 58: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group (000), 20112018 62
Table 59: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Sector (000), 20112018 63
Table 60: Seasonal Influenza Vaccine Market, Germany, Vaccine Cost ($), 20112018 63
Table 61: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 20112018 64
Table 62: Seasonal Influenza Vaccine Market, Japan, Population (000), 20112018 66
Table 63: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 20112018 67
Table 64: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage (000), 20112018 68
Table 65: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (000), 20112018 68
Table 66: Seasonal Influenza Vaccine Market, Japan, Total Number of Doses (000), 20112018 69
Table 67: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group (000), 20112018 69
Table 68: Seasonal Influenza Vaccine Market, Japan, Vaccine Cost ($), 20112018 70
Table 69: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 20112018 71
Table 70: Seasonal Influenza Vaccine Market, Promising Vaccines by Phase of Development and Company, 2012 80
Figure 1: Seasonal Influenza Vaccine Market, Top Seven Countries, Population (000), 20112018 15
Figure 2: Seasonal Influenza Vaccine Market, Top Seven Countries, Vaccination Coverage by Age Group (%), 20112018 16
Figure 3: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Doses by Age Group (000), 20112018 18
Figure 4: Seasonal Influenza Vaccine Market, Top Seven Countries, Revenue Forecasts ($m), 20112018 19
Figure 5: Seasonal Influenza Vaccine Market, Top Seven Countries, Drivers and Restraints 20
Figure 6: Seasonal Influenza Vaccine Market, The US, Population (000), 20112018 23
Figure 7: Seasonal Influenza Vaccine Market, The US, Vaccination Coverage by Age Group (%), 20112018 24
Figure 8: Seasonal Influenza Vaccine Market, The US, Number of Doses by Age Group (000), 20112018 26
Figure 9: Seasonal Influenza Vaccine Market, The US, Revenue Forecasts ($m), 20112018 28
Figure 10: Seasonal Influenza Vaccine Market, The US, Drivers and Restraints 29
Figure 11: Seasonal Influenza Vaccine Market, The UK, Population (000), 20112018 30
Figure 12: Seasonal Influenza Vaccine Market, The UK, Vaccinated Coverage by Age Group (%), 20112018 32
Figure 13: Seasonal Influenza Vaccine Market, The UK, Number of Doses by Age Group (000), 20112018 34
Figure 14: Seasonal Influenza Vaccine Market, The UK, Revenue Forecasts ($m), 20112018 36
Figure 15: Seasonal Influenza Vaccine Market, The UK, Drivers and Restraints 37
Figure 16: Seasonal Influenza Vaccine Market, France, Population (000), 20112018 38
Figure 17: Seasonal Influenza Vaccine Market, France, Vaccination Coverage by Age Group (%), 20112018 39
Figure 18: Seasonal Influenza Vaccine Market, France, Number of Doses by Age Group (000), 20112018 41
Figure 19: Seasonal Influenza Vaccine Market, France, Revenue Forecasts ($m), 20112018 43
Figure 20: Seasonal Influenza Vaccine Market, France, Drivers and Restraints 44
Figure 21: Seasonal Influenza Vaccine Market, Italy, Population (000), 20112018 45
Figure 22: Seasonal Influenza Vaccine Market, Italy, Vaccination Coverage by Age Group (%), 20112018 46
Figure 23: Seasonal Influenza Vaccine Market, Italy, Number of Doses by Age Group (000), 20112018 48
Figure 24: Seasonal Influenza Vaccine Market, Italy, Revenue Forecasts ($m), 20112018 50
Figure 25: Seasonal Influenza Vaccine Market, Italy, Drivers and Restraints 51
Figure 26: Seasonal Influenza Vaccine Market, Spain, Population (000), 20112018 52
Figure 27: Seasonal Influenza Vaccine Market, Spain, Vaccination Coverage by Age Group (%), 20112018 53
Figure 28: Seasonal Influenza Vaccine Market, Spain, Number of Doses by Age Group (000), 20112018 55
Figure 29: Seasonal Influenza Vaccine Market, Spain, Revenue Forecasts ($m), 20112018 57
Figure 30: Seasonal Influenza Vaccine Market, Spain, Drivers and Restraints 58
Figure 31: Seasonal Influenza Vaccine Market, Germany, Population (000), 20112018 59
Figure 32: Seasonal Influenza Vaccine Market, Germany, Vaccination Coverage by Age Group (%), 20112018 60
Figure 33: Seasonal Influenza Vaccine Market, Germany, Number of Doses by Age Group (000), 20112018 62
Figure 34: Seasonal Influenza Vaccine Market, Germany, Revenue Forecasts ($m), 20112018 64
Figure 35: Seasonal Influenza Vaccine Market, Germany, Drivers and Restraints 65
Figure 36: Seasonal Influenza Vaccine Market, Japan, Population (000), 20112018 66
Figure 37: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (%), 20112018 67
Figure 38: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group (000), 20112018 69
Figure 39: Seasonal Influenza Vaccine Market, Japan, Revenue Forecasts ($m), 20112018 70
Figure 40: Seasonal Influenza Vaccine Market, Japan, Drivers and Restraints 71
Figure 41: Seasonal Influenza Vaccine Market, Regulatory Authorities, The US, 2012 73
Figure 42: Seasonal Influenza Vaccine Market, Drug Approval Process, The US, 2012 74
Figure 43: Seasonal Influenza Vaccine Market, Regulatory Authorities, EU, 2012 75
Figure 44: Seasonal Influenza Vaccine Market, Approval Process, EU, 2012 76
Figure 45: Seasonal Influenza Vaccine Market, Regulatory Authorities, Japan, 2012 77
Figure 46: Seasonal Influenza Vaccine Market, Drug Approval Process, Japan, 2012 77
Figure 47: Seasonal Influenza Vaccine Market, Top Seven Countries, R&D Pipeline by Phase (%), 2012 79
Figure 48: Seasonal Influenza Vaccine Market, Top Seven Countries, Market Share (%), 2011 83
Figure 49: Seasonal Influenza Vaccine Market, Top Seven Countries, Sanofi, SWOT Analysis 85
Figure 50: Seasonal Influenza Vaccine Market, Top Seven Countries, GSK, SWOT Analysis 86
Figure 51: Seasonal Influenza Vaccine Market, Top Seven Countries, Novartis, SWOT Analysis 87
Figure 52: Seasonal Influenza Vaccine Market, Top Seven Countries, AstraZeneca, SWOT Analysis 88
Figure 53: Seasonal Influenza Vaccine Market, Top Seven Countries, Deals by Type, 20092012 89
Figure 54: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Deals by Year, 20092012 90
Figure 55: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Geography, 20092012 93
Figure 56: Seasonal Influenza Vaccine Market, Top Seven Countries, M&A Deals by Year, 20092012 94
Figure 57: Seasonal Influenza Vaccine Market, Top Seven Countries, Licensing Agreements by Geography, 20092012 96
Figure 58: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Licensing Agreements by Year, 20092012 97
Figure 59: Seasonal Influenza Vaccine Market, Top Seven Countries, Partnership Deals by Geography, 20092012 100
Figure 60: Seasonal Influenza Vaccine Market, Top Seven Countries, Number of Partnership Deals by Year, 20092012 101
Figure 61: GBI Research Market Forecasting Model, Estimation of Market for a Country, 2010 105